



European Cancer
Patient Coalition

Health Technology Assessment eLearning Module

Max Schravendeel
Health & Research Officer



European Cancer
Patient Coalition

ECPC on HTA

- Advocating for harmonised HTA in the EU since 2014
- Launch of **The European Bill of Cancer Patient's Rights**
 - Endorsed by **MEP Elizabetta Gardini**
 - Supported by more than **250 MEPs**.
- EU cooperation on HTA around **regulation 726/2004**
- ECPC position paper on the 2017 European Parliament report on the **Options for Improving Access to Medicines**






HTA in the European Union

European Commission legislative proposal for Future EU Cooperation on HTA:

- Better outcomes for patients and society
- Differences leading to delays and variations in approval decisions and inequities in access.
- Very few HTA agencies involve patients in their assessments
- Wasteful duplication of efforts/resources





European Cancer
Patient Coalition

ECPC HTA eLearning module

On World Cancer Day, 4 Feb 2019, ECPC launched the **eLearning module on Health Technology Assessment**

- Increasing knowledge and confidence for ECPC members and the wider cancer patient community
- Advocate for patient involvement where there are no established frameworks





European Cancer
Patient Coalition

Why it matters?

“We advocate for actively involving patient organisations in all decision-making processes, including Health Technology Assessment, for the protection of individual human health and for the overall public health.”

The European Cancer Patient Coalition calls for:

- Systematic involvement of patient organisations in HTA
- Formalisation of patient organisation involvement
 - throughout all activities of HTA at EU level
 - in the assessments of non-clinical domains that are conducted at the national level.



Why it matters?

- Over 50 national and regional HTA bodies in the EU
- Each Member State decides individually, which medicines should be reimbursed by the health systems, and at what price
- Variations in decision-making and the lack of a harmonised HTA policy, results in unacceptable delays
- Many cancer patients in the EU still cannot access life-saving medicines
- Mandatory patient involvement in HTA due to legal, ethical, patient and social aspects



How we got here

- Developed in partnership with experts
- Draft concept was presented at the Annual Congress 2018
- Feedback from over 40 ECPC members
- ECPC Board closely involved





HTA eLearning Module

The module covers a range of information:

- Medicines development process and their examination as part of HTA
- Cancer treatment reimbursement
- How cancer patient organisations can get involved in HTA.
- Recent legislative developments on HTA at the EU level
- Importance of involvement of patient organisations/advocates in HTA.

Menu | Glossary | Exit

Introduction	<h2>Why is HTA Important Now?</h2> <p>1. Europe of disparities, ECPC 2015</p> <p>Previous [Progress Indicators] Next</p>
What is HTA?	
Involvement of patient organisations in the HTA process	
How is the value of cancer treatments measured?	
Why do some countries reimburse a cancer treatment and others do not?	
Call to action!	

Menu | Glossary | Exit

Introduction	<h2>What is HTA?</h2> <ul style="list-style-type: none">• HTA is a process that evaluates the clinical, economic and societal implications of a new medicine. i• HTA acts as a 'bridge' between EMA and, Pricing and Reimbursement. It seeks to provide health policy-makers with evidence-based information to guide their decisions about whether new medicines should be introduced.• The information provided by the HTA gives policy makers a measure of the added value of funding a new medicine compared to the current standard of care. The national healthcare system then decides if they will fund a new medicine.• HTA is done differently in different countries, each country has its own value framework even though it might not be formally called HTA. <p>Previous [Progress Indicators] Next</p>
What is HTA?	
Involvement of patient organisations in the HTA process	
How is the value of cancer treatments measured?	
Why do some countries reimburse a cancer treatment and others do not?	
Call to action!	



HTA eLearning Module

Focus on patient
input as part of
the HTA process:

- Where?
- How?
- What?

Menu | Glossary | Exit

Where Can Patients Provide Input?

Click on the hotspots buttons to view how patients can input into the various components of HTA:

Introduction

What is HTA?

Involvement of patient organisations in the HTA process

How is the value of cancer treatments measured?

Why do some countries reimburse a cancer treatment and others do not?

Call to action!

Previous

Next

EUROPEAN
CANCER
PATIENT
COALITION



HTA eLearning Module

How is the value of cancer treatments measured?

- Clinical benefit
- Cost-effectiveness
- Differences

Menu | Glossary | Exit

EUROPEAN
CANCER
PATIENT
COALITION

Chapter 4: How is the Value of Cancer Treatments Measured?

Previous Next Start

Menu | Glossary | Exit

Introduction	<h3>The System is Different in Different Countries</h3> <p>Not all EU Member States have a formal HTA process. In countries that do, the process and the organisation(s) responsible is often different between countries.</p> <p>All HTA processes consider the added clinical benefit of a new medicine, however, the emphasis on cost-effectiveness varies.</p> <p>To see examples of how HTA differs between countries, click on the buttons below:</p> <div style="display: flex; justify-content: space-around;"><div>Some countries have one national HTA organisation</div><div>Some countries have more than one organisation responsible for HTA</div><div>Some countries do not have a dedicated HTA organisation</div></div> <div style="display: flex; justify-content: space-around;"><div>Some countries have formal methods for assessing cost-effectiveness</div><div>In some countries, patients have co-payments to cover the cost of a drug</div><div>In some countries, the HTA decision is advisory rather than binding</div></div> <p>Click here to learn more about the different HTA processes between countries.</p>
What is HTA?	
Involvement of patient organisations in the HTA process	
How is the value of cancer treatments measured?	
Why do some countries reimburse a cancer treatment and others do not?	
Call to action!	Previous Next

EUROPEAN
CANCER
PATIENT
COALITION



European Cancer
Patient Coalition

HTA eLearning Module

Supporting Booklet

- Further information and useful links to further explore the topics addressed in the module
- eLearning Module first, booklet second



EUROPEAN
CANCER
PATIENT
COALITION

Understanding Health Technology Assessment:
A Guide for Patients

Supporting Booklet

Thank you for completing the online eLearning module 'Understanding Health Technology Assessment'. This booklet provides further information and useful links in case you want to explore the topics covered in the online module any further.



Evaluation survey

- Help us identify the countries and languages to adapt the content of the module to
- We are working on bringing translated and localized content of eLearning module to your countries!

Evaluation Survey - ECPC HTA eLearning Module

Tell us what you thought about the HTA eLearning module

Thank you for exploring the latest ECPC eLearning module on Health Technology Assessment. We hope you found it useful!

To help us improve the module in the future, and to better understand the needs of patient advocates and patient organisations across Europe and beyond, we would appreciate if you could take 5 minutes to answer this questionnaire.

If you would like to provide more detailed feedback, please contact us at info@ecpc.org

OK



European Cancer
Patient Coalition

Thank You!

For any questions about eLearning module, or if you would like to get involved in bringing the eLearning module to your country, please make sure to complete the evaluation survey and contact:

Alex Filicevas, Head of EU Affairs

Alex.Filicevas@ecpc.org